February 28, 2023 — 08:35 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Tuesday that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled "Use of Bremelanotide in Patients with Controlled Hypertension."
This issued patent further strengthens the Company's intellectual property position and coverage for the Company's approved therapeutic product for hypoactive sexual desire disorder in premenopausal women, Vyleesi.
The patent has, with patent terms adjustments, a term through April 29, 2041. The claims of the patent relate to use of bremelanotide, marketed by the Company under the trade name Vyleesi, for treatment of female sexual dysfunction in patients with controlled hypertension. The patent is solely owned by the Company. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.